Whole genome scanning tested for clinical decision making.
DANIEL S. LEVINE
The Burrill Report
A French research consortium presented the findings from their study at the 2012 European Society for Medical Oncology Congress in Vienna. The results were based on biopsies performed in 402 breast cancer patients, including 26 patients for whom analyses are ongoing.
for complete article:
http://www.burrillreport.com/article-breast_cancer_study_points_to_personalized_treatments.html
“The French consortium has opened a new door to more personalized treatment of advanced breast cancer.”
A first-of-its-kind, large scale trial of whole genome cancer testing to personalize treatment for patients with metastatic breast cancer finds in 20 percent of the cases uncovered rare and unexpected genomic activity and argues it’s time to make this approach a clinical standard.A French research consortium presented the findings from their study at the 2012 European Society for Medical Oncology Congress in Vienna. The results were based on biopsies performed in 402 breast cancer patients, including 26 patients for whom analyses are ongoing.
for complete article:
http://www.burrillreport.com/article-breast_cancer_study_points_to_personalized_treatments.html
No comments:
Post a Comment